It had the effect of synergistic anti-BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutation melanoma cell proliferation with RAF kinase inhibitor [70], and synergistic anti-ALK (anaplastic lymphoma kinase) mutation neuroblastoma with ALK inhibitor and prolonged survival [71]. This evidence concerns the gene BRAF and neuroblastoma.